1,4-Dihydropyridines as calcium channel ligands and privileged structures.
about
1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative StressStructural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congenersA Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI MiceMolecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.Role of l-Ca(2+) channels in intestinal pacing in wild-type and W/W(V) mice.Acute atrial arrhythmogenesis in murine hearts following enhanced extracellular Ca(2+) entry depends on intracellular Ca(2+) stores.Principal component analysis of HPLC retention data and molecular modeling structural parameters of cardiovascular system drugs in view of their pharmacological activity.Diethyl 4-(biphenyl-4-yl)-2,6-dimethyl-1,4-di-hydro-pyridine-3,5-di-carboxyl-ateOne-pot synthesis of highly functionalized pyridines via a rhodium carbenoid induced ring expansion of isoxazoles.Alternative splicing modulates diltiazem sensitivity of cardiac and vascular smooth muscle Ca(v)1.2 calcium channels.The effect of bromine scanning around the phenyl group of 4-phenylquinolone derivatives.The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases.Synthetic Utility of Epoxides for Chiral Functionalization of Isoxazoles.Computational studies to predict or explain G protein coupled receptor polypharmacologyDifferential effects of furnidipines' metabolites on reperfusion-induced arrhythmias in rats in vivo.Novel synthesis of a series of spiro 1,3-indanedione-fused dihydropyridines through the condensation of a tetrone with N-aryl/alkylenamines in presence of solid support silica sulfuric acid.Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captoprilPractical Radiosynthesis and Preclinical Neuroimaging of [11C]isradipine, a Calcium Channel Antagonist.Disrupting calcium channel expression to lower blood pressure: new targeting of a well-known channelVascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA as a potential antihypertensive therapyPeripheral chemoreceptors: function and plasticity of the carotid body.TRPA1 modulators in preclinical development.1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.Calcium-permeable ion channels in pain signaling.4-isoxazolyl-1,4-dihydropyridines: a tale of two scaffolds.Murine Electrophysiological Models of Cardiac Arrhythmogenesis.Functional expression of voltage-gated calcium channels in human melanoma.Design, synthesis and evaluation of cytotoxicity of novel chromeno[4,3-b]quinoline derivatives.Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's diseaseDihydropyridines' metabolites-induced early apoptosis after myocardial infarction in rats; new outlook on preclinical study with M-2 and M-3.Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.Structural model for phenylalkylamine binding to L-type calcium channels.Bilayer properties of giant magnetic liposomes formed by cationic pyridine amphiphile and probed by active deformation under magnetic forces.Analysis of the action of compounds that inhibit the germination of spores of Bacillus species.A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine.Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.The multicomponent Hantzsch reaction: comprehensive mass spectrometry monitoring using charge-tagged reagents.Application of electron conformational-genetic algorithm approach to 1,4-dihydropyridines as calcium channel antagonists: pharmacophore identification and bioactivity prediction.A Simple and Advantageous Synthesis of the Privileged 1,4-Benzodiazepine Nucleus1,4-Dihydropyridine Calcium Channel Blockers: Homology Modeling of the Receptor and Assessment of Structure Activity Relationship
P2860
Q26765819-6FE3D799-3921-4A83-8DC8-3C9839DE73A3Q28539094-3348EF91-1281-494D-A1AF-8560D54E1E1FQ28547847-4749E315-B55F-43DB-849D-95E0D8CE9A98Q30437204-07745E98-643F-420E-8BA8-BD99F020E762Q33207929-BBDB23C4-5018-4268-A2CC-C9BE90E718E0Q33514742-740BA367-BF6D-4EE2-8779-9C23AED9AFFCQ33662066-A861B29C-4F29-47C0-AB25-9EFFF3C593DDQ33997231-B85A52DD-5965-4A9D-824E-529EC6822922Q34067058-D2219321-EE6A-41EF-96A2-D0337AA5161FQ34116779-B26FFBFB-AD0E-4371-8A53-C47FF1E3537AQ34238780-5AE32575-60E2-4AEB-AEC2-3240ACEA3E97Q34286572-7C8D4586-BB37-4870-9865-3F6707EBC554Q34333209-3A44CA12-461F-469D-8DFE-31E5CAA90B59Q35039998-9DB6A5A1-38EA-48DB-931D-D3BFFC2A47E6Q35107416-4CC7425E-5901-486B-96FE-9CC224FCFA26Q35584908-6186BB06-F1CA-49F5-B2FF-E94EFA861F8BQ36411375-0C4AFCAC-2F52-4DD8-9118-79C2097E89F7Q36909610-56267581-C7BD-4B51-98A7-049EB4C3C22DQ37029616-C5BEA324-D799-4CE0-B1B9-E2CEB65384D4Q37168490-22AF060B-CF12-46DD-8EC6-F36C6DDEBF13Q37572329-4210D094-CEDE-40D3-8AFA-0F6247A8CF42Q37638751-3C870638-2C9E-4C50-984C-FE74034B2D4AQ38125687-BB1111FD-0488-4169-9CA0-38B12979A919Q38175134-A92D4BB6-D861-4241-ACE4-D2FC6E05E109Q38223015-1B6BBB40-B049-48D8-8720-5F0510B41E9CQ39038606-77F7A1F0-BD4C-419F-8522-F00D041D3390Q39409759-F3B4B75E-8467-4463-8E4A-F6EB2B2DDADDQ39598580-A777598C-AF8C-44FF-95A4-734707346D8AQ41245399-5918AC60-9904-4CBF-BA6F-6FB20F145E16Q42015200-69A0CE3A-9AA0-46A5-896C-D9A576F5E498Q42197966-FE474809-BAF6-4080-9C27-2FC7BE10EC40Q42961133-1975DBB2-5D31-4BA4-B9AE-BB18FB9E4909Q43636111-CB4632B8-FD9A-4F6F-BC0F-C8C557A49699Q44794166-8F95EE8B-1D37-4AA6-A769-9AF1D6CC0856Q46966343-D846C24D-F528-4E3E-88E6-1F04D3268106Q48172109-CE1087D4-B31D-4B9A-9B4A-16C6272719E0Q51058568-11766EE1-C788-4172-B833-B41E93047187Q51583668-6C9C8B7F-0522-4624-A008-02BDA5037261Q59043447-A9FC70C9-FD29-4C01-A743-84B5C9E09EBAQ59047553-DF1FA7EE-967C-4445-B7BD-2ABDA8412932
P2860
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@ast
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@en
type
label
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@ast
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@en
prefLabel
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@ast
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@en
P356
P1476
1,4-Dihydropyridines as calcium channel ligands and privileged structures.
@en
P2093
David J Triggle
P2888
P304
P356
10.1023/A:1023632419813
P577
2003-06-01T00:00:00Z
P6179
1044056903